Kenya Ebola update, Liquidia’s Yutrepia settlement and reliable electricity for healthcare.
Kenya confirmed a second Ebola case involving a close relative of the first patient. The man was already in quarantine and was isolated after developing symptoms; the Ministry of Health reported no evidence of wider community transmission.
Why it matters: A significant development since the earlier surveillance update, reinforcing the importance of contact monitoring and rapid isolation.
Read at Reuters →Liquidia announced a settlement resolving six lawsuits with United Therapeutics, involving net payments totalling $380.7 million. Yutrepia will remain available for pulmonary arterial hypertension, while Liquidia has stopped promoting it for pulmonary hypertension associated with interstitial lung disease and submitted a request to remove that indication from its label.
Why it matters: Clarifies the product’s commercial direction and highlights how patent settlements can affect indications, promotion and patient access.
Read at Liquidia →An updated WHO fact sheet estimates that almost one billion people in lower-income countries are served by facilities with unreliable electricity or none at all. Drawing on existing survey evidence, it highlights rural disparities and calls for investment in reliable power, including solar systems with battery storage.
Why it matters: Reliable electricity underpins diagnostics, vaccination, safe childbirth and emergency care—making energy infrastructure a practical healthcare priority.
Read at WHO →Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.